ABSTRACT: Benzoquinazolinone 1 is a positive allosteric modulator (PAM) of the M 1 muscarinic acetylcholine receptor (mAChR), which is significantly more potent than the prototypical PAM, 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA). In this study, we explored the structural determinants that underlie the activity of 1 as a PAM of the M 1 mAChR.
INTRODUCTION
Alzheimer's disease is a progressive and irreversible neurodegenerative disorder affecting around 25 million people worldwide. 1 The disorder is primarily observed in the ageing population, and characteristic symptoms of the disease include memory loss, confusion and dementia.
2, 3
Currently, pharmacological interventions for Alzheimer's disease remain limited, and provide only symptomatic relief to patients. 4, 5 The reduction of cholinergic neurons in the basal nuclear complex is associated with the cognitive deficits observed in patients with Alzheimer's disease. 6, 7 A link between mAChR function and disease pathology has been suggested, with the M 1 mAChR subtype particularly highlighted for a role in cognition. 7, 8 Acetylcholinesterase inhibitors are currently used to treat the cognitive deficits associated with
Alzheimer's disease, but this approach is limited by the moderate improvement in the cognitive function of patients, as well as debilitating side effects including nausea, diarrhea, hypotension and vomiting. 9 However, because acetylcholine esterase inhibitors act to inhibit acetylcholine breakdown they exert a non-selective effect at all muscarinic receptor subtypes. It is likely that such side-effects are due activation of M 2 and M 3 mAChRs expressed in the periphery. 7 Accordingly, there has been considerable focus upon the design of ligands that selectively activate the M 1 mAChR. However, the design of selective orthosteric agonists for the M 1 mAChR has proven difficult, due to the highly conserved orthosteric pocket of all the mAChRs (M 1 -M 5 ). 10 However, efforts to target the less-conserved, and topographically distinct allosteric site of the receptor have proven more fruitful. [11] [12] [13] [14] Ligands that target such allosteric sites may act to potentiate the binding and signaling activity of an orthosteric receptor agonist (positive allosteric modulators, PAM) and/or activate the receptor themselves (allosteric agonists). Allosteric ligands of the M 1 mAChR have been recognized as a potentially promising novel drug class for the treatment of Alzheimer's disease. BQCA was reported as the first highly selective PAM for the M 1 mAChR. 15 Structure-activity relationship (SAR) studies around BQCA have revealed structurally related compounds with higher affinity and potency. [16] [17] [18] Furthermore, our group has reported an enriched SAR study that used modeling of pharmacological data, to relate structural modification to BQCA analogues, with variations in binding affinity (pK B ), binding (α) and functional (αβ) cooperativity and intrinsic efficacy (τ B ). 19 3-((1S,2S)-2-Hydroxycyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one (1) , is a significantly more potent M 1 mAChR PAM with a structural ancestry originating from BQCA and related compounds ( Figure 1 ). 17, 20 We recently used a combination of site-directed mutagenesis, modelling of pharmacological data and molecular dynamics simulations to propose a binding mode for 1 at the M 1 mAChR, similar to that predicted 
RESULTS AND DISCUSSION
Chemistry. The synthesis of lead compound 1, though previously reported in patent literature, 20 has only recently been fully optimized and characterized in our hands. 21 Seeking to understand the basis for the PAM activity of compound 1, we initially decided to pharmacologically characterize key synthetic intermediates. Compound 10 was synthesized as previously described, with subsequent Negishi coupling carried out according to established methodology, 20 3 ) 2 , degassed anhydrous THF, 0 °C; ii. 0.5 M (2-chloro-5-pyridyl)methylzinc chloride/THF, 0 °C to rt, 79%; (b) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, cat. PdCl 2 (PPh 3 ) 2 , 1 M Na 2 CO 3(aq) /THF 1:3 degassed, 100 °C, 64% (59% 1 : 5% 12).
Aside from pharmacological characterization of compounds 10, 12 and 1, which represent a stepwise build-up of the (pyridin-3-yl)methyl pendant group, we also sought to investigate the nature of the polyaromatic core. Given the precedence for polyaromatic heterocycles potentially imparting toxic DNA-chelation behavior to a scaffold, 22 quinazolin-4(3H)-one core. The deletion of the fused benzene ring was also anticipated to make these analogues more "drug-like", through reductions in lipophilicity (assessed through calculated log P), topological polar surface area (tPSA) and molecular weight. 23 With this strategy in mind, we synthesized analogues with either complete deletion of the peripheral fused benzene ring (2), or the presence of one or two methyl groups in the 7/8 positions of the quinazolin-4(3H)-one core, to
give 4, 5 and 6. Evaluation of these compounds was anticipated to address whether the peripheral fused benzene ring of literature compound 1, could be replaced by the steric presence of either one or two methyl groups.
Our recent work determining the structural nature of the interaction of compound 1 with the allosteric binding site at the M 1 mAChR, highlighted the importance of Y179 in ECL2, making aromatic edge-face interactions with both the benzylic pendant group and benzo[h]quinazolin-4(3H)-one core. 21 In addition, the proximity of the phenol moiety of Y179 could facilitate additional polar interactions with an appropriately positioned heteroatom incorporated into the ligand. With this in mind, we also synthesized 8, the pyrido[2, 3-d] pyrimidin-4(3H)-one analogue of 2.
Synthesis of these analogues was carried out in a similar manner to that of lead compound 1. In the case of 2, commercially available 2-amino-5-bromobenzoic acid (21) was employed, while the remaining substituted 2-amino-5-bromobenzoic acid intermediates (22) (23) (24) , required synthesis from unbrominated starting materials.
2-Amino-3,4-dimethylbenzoic acid (14) underwent initial Fischer esterification to give the corresponding methyl ester 15, followed by selective bromination of the 5-position to give intermediate 16 as the hydrobromide salt, in excellent yield. Subsequent basic hydrolysis afforded the desired 2-amino-5-bromo-3,4-dimethylbenzoic acid (24) . In the case of 2-amino-3-methylbenzoic acid (13), we were able to directly brominate in acetic acid at room temperature, to
give 22, without the need for esterification of the carboxylic acid moiety (Scheme 2). Finally, in the case of 2-amino-4-methylbenzoic acid (23) , our attempts at direct bromination in the same 7 manner as for 22, gave a mixture of mono-and dibrominated products, in addition to unreacted starting material, which proved difficult to separate. However, selective bromination in the 5-postion was achieved through esterification of the carboxylic acid moiety, and acetylation of the aniline group. The acetanilide derivative 19 facilitated selective mono-bromination of the 5-position, allowing the isolation of 23 following the saponification of the ester in the modest yield over 19% over these two steps.
Subsequent synthetic steps proceeded in accordance with our reported synthesis of lead compound 1. 21 Briefly, the 2-amino-5-bromobenzoic acid (21) (22) (23) (24) intermediates firstly underwent Installation of the (pyridin-3-yl)methyl pendant group was achieved as described for lead compound 1, through a sequence of Negishi and Suzuki reactions, to give the desired compounds 2 and 4-6, bearing the (6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl group. During Suzuki coupling of final compounds 2 and 6, appreciable amounts of the dehalogenation side-product, 3
and 7 were also isolated, and deemed of interest for pharmacological evaluation. 3 ) 2 , dry THF, 0 °C; ii. 0.5 M (2-chloro-5-pyridylmethyl)zinc chloride/THF, 0 °C to rt or 55 °C, 14-90%; (n) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, cat. PdCl 2 (PPh 3 ) 2 , 1 M Na 2 CO 3(aq) /THF 1:3 degassed, 100 °C, Suzuki product 15-96%, dehalogenation product 0-14%.
As part of the strategy to develop fused heteroaromatic analogues of lead compound 1, the investigation of alternative cores was also of interest. The pyrido[2, 3- 
24-26
The thieno[2,3-d]pyrimidin-4(3H)-one core was accessible through synthesis of the appropriately substituted 2-aminothiophene-3-carboxamide, which in turn was assembled in a one-pot Gewald synthesis based on literature precedent. 5 Components for the Gewald reaction were readily synthesized from commercially available reagents (Scheme 4). Cyanoacetamide 48, was obtained 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 through HCTU-mediated coupling of cyanoacetic acid and (1S,2S) We elected to synthesize 9 bearing the biphenylmethyl pendant group, for initial ease of access and to establish synthetic methodology.
Furthermore, this moiety has been shown to impart good affinity and cooperativity on the BQCA scaffold (an early precursor of lead compound 1 and related structures).
7

PHARMACOLOGY
We recently published an SAR study of the M 1 mAChR PAM, BQCA. 19 By incorporating modeling into our pharmacological analysis, we were able to relate modifications of the structural features of BQCA, to changes in parameters that describe allosteric ligand action. These comprise the affinity of the modulator for the free receptor (K B ), its modulatory effects on the binding and efficacy of acetylcholine (α and β, respectively), and its intrinsic efficacy (direct allosteric agonism)
in the system (τ B ). In particular, alternative substitution of the quinolone ring in the 5-and 8-positions modulated intrinsic efficacy; isosteric replacement of the carboxylic acid moiety or amide derivatives of the acid function was important in determining cooperativity, and replacement of the N-alkyl group modulated ligand affinity. 19 More recently, we focused on the binding mode of 3-
, a significantly more potent M 1 mAChR PAM with a structural ancestry originating from BQCA. 21 To understand the structural determinants that underlie the superior PAM activity of 1, we applied the same approach as described above for BQCA for all ligands described in this study. As described before, 1 displays a significant 13-fold higher affinity (K B = 1. 13 addition of a methyl group at both the 7-and 8-positions in compound 6 caused a 7-fold increase in affinity, and no significant change in cooperativity with ACh or intrinsic efficacy relative to 2.
Indeed this analogue displayed a 2-fold higher intrinsic efficacy than 1. Together these data reveal that the benzo[h]quinazolin-4(3H)-one core is an important determinant of the affinity of 1.
Deletion of the fused benzene ring of this core (2) was associated with a significant loss of affinity that was partly rescued with the addition of methyl groups in the 7 and/or 8 position of a quinazolin-4(3H)-one core (5 and 6). Indeed, compound 5 displayed no significant difference in affinity compared to 1 (p > 0.05, one-way ANOVA with Tukey's post-test). In our recent SAR study, 19 we observed that the replacement of the N-alkyl group of the quinolone core of BQCA modulated ligand affinity. In particular, changing the N-(4-methoxy)benzyl group to N-(4-phenyl)benzyl tended to improve affinity for the receptor without improving cooperative binding with ACh. In contrast, the absence of a 4-(1-methylpyrazole-4-yl) substituent from the (pyridin-3-yl)methyl pendant group of 2 (with a quinazolin-4(3H)-one core) had no effect upon affinity but instead caused a decrease in intrinsic activity (compare compounds 2 and 3). However, when two methyl groups were present on the quinazolin-4(3H)-one core, the absence of the 4-(1-methylpyrazole-4-yl) moiety caused no change in affinity, cooperativity or intrinsic activity (6 compared to 7, Table 1 ).
To further explore the role of the (pyridin-3-yl)methyl pendant group in the determination of the activity of 1, we characterized the synthetic intermediates 10 and 11 and synthetic byproduct 12.
Replacement of the (6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl group with a bromosubstituent (10) caused an 8-fold loss of affinity, a 170-fold and 70-fold loss in binding and functional cooperativity with ACh, respectively. In addition, a complete loss of intrinsic efficacy was observed. Compound 12, which possessed an unsubstituted (pyridin-3-yl)methyl group, displayed an affinity for the M 1 mAChR that was not significantly different from 1 and had similar binding and functional cooperativity with ACh (α = 223, αβ = 436). Furthermore, 12 displayed 5-fold higher intrinsic efficacy than 1 (τ B = 14). In contrast, the (6-chloropyridin-3-yl)methyl the importance of the benzylic pendant group for the activity of 1. In contrast to our findings with BQCA, we found that this moiety was not only important for affinity, but also for the cooperativity with ACh and intrinsic efficacy displayed by 1. However, removal of the 4-(1-methylpyrazole-4-yl) substitution of the (pyridin-3-yl)methyl pendant group of 1 was tolerated both in terms of affinity, cooperativity with ACh and intrinsic efficacy. 
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CONCLUSIONS
We have recently reported that 3-
, while structurally related to BQCA, is a significantly more potent PAM of the M 1 mAChR, driven both by an increased affinity for the M 1 mAChR and an increased level of positive cooperativity with ACh. 21 In addition, 1 displays higher intrinsic efficacy than BQCA. Furthermore, we recently proposed a binding mode of 1 within the M 1 mAChR that is similar to that predicted for BQCA. 21 In this study, we wanted to explore the structural determinants that underlie the activity of 1 as a PAM of the M 1 mAChR. We have previously demonstrated that changing the N-alkyl group of the quinolone core of BQCA modulated ligand affinity but not cooperativity with ACh. 19 In this study we demonstrate that the (pyrid-3-yl)methyl pendant group of 1 is not only important for affinity, but has an additional role in determining cooperativity with ACh. In addition we found that removal of the 1-methyl-1H-pyrazol-4-yl moiety of 1 was well tolerated in terms of both affinity and cooperativity with ACh and generated a PAM (7) C NMR spectra were recorded on a Bruker Avance Nanobay III 400MHz
Ultrashield Plus spectrometer at 400.13 MHz and 100.62 MHz respectively. Chemical shifts (δ) are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent.
Coupling constants (J) and carbon-fluorine coupling constants (J CF ) are recorded in Hz and the significant multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), doublet of triplets (dt). Spectra were assigned using appropriate COSY, distortionless enhanced polarisation transfer (DEPT), HSQC and HMBC sequences. Specific optical rotation was determined using a Jasco P-2000 polarimeter.
LCMS were run to verify reaction outcome and purity using following system: Agilent 6120 Series 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 with a Poroshell 120 EC-C18 50 x 3.0 mm 2.7 micron column, and a flow rate of 0.5 mL/min and total run time of 5 min; 0-1 min 95% buffer A and 5% buffer B, from 1-2.5 min up to 0% buffer A and 100% buffer B, held at this composition until 3.8 min, 3.8-4 min 95% buffer A and 5% buffer B, held until 5 min at this composition. Mass spectra were acquired in positive and negative ion mode with a scan range of 100-1000 m/z. UV detection was carried out at 214 and 254 nm. All retention times (t R ) are quoted in minutes. High resolution mass spectra (HRMS) were obtained from a Waters LCT Premier XE (TOF) mass spectrometer fitted with an ESI ion source, coupled to a 2795 Alliance Separations Module.
Preparative HPLC was performed using an Agilent 1260 infinity coupled with a binary preparative pump and Agilent 1260 FC-PS fraction collector, using Agilent OpenLAB CDS software (Rev C.01.04), and an Altima 5µM C8 22 x 250 mm column. The following buffers were used; buffer A:
H 2 O; buffer B: MeCN, with sample being run at a gradient of 5% buffer B to 100% buffer B over 20 min, at a flow rate of 20 mL/min All screening compounds were of > 95% purity unless stated otherwise.
General Procedure A: HCTU-mediated amide bond formation. Carboxylic acid (1 eq), HCTU (1.1 eq) and amine or amine salt (1.1 eq) were dispersed or dissolved in DMF (~2 mL/mmol) at RT. To this was added DIPEA (2.5 eq, for amine salts, an additional 1.0 eq per salt form was also added), and the mixture allowed to stir at RT overnight. LCMS analysis was used to confirm reaction completion. The mixture was diluted with water/sat. NaHCO 3(aq) (1:1, ~20 mL/mmol) and stirred for 30 min at RT. Where a solid precipitate formed, this was collected by filtration (vacuum) and washed with water. Where no solid could be isolated in this manner, the aqueous slurry was extracted with EtOAc (3 times) and the combined organic layers washed with brine, then concentrated under reduced pressure. Where necessary, further purification was carried out by FCC.
21
General Procedure B: Negishi coupling of aryl bromides with (2-chloro-5-pyridylmethyl)zinc
chloride. Aryl bromide (1.0 eq) was dissolved in dry THF (2 mL/mmol), under an atmosphere of nitrogen, and degassed for 5 min under a stream of nitrogen. Pd(P( t Bu) 3 purified by normal phase silica chromatography as specified under each monologue. 
3-((1S,2S)-2-Hydroxycyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)quinazolin-4(3H)-one (2) and 3-((1S,2S)-2-Hydroxycyclohexyl)-6-(pyridin-3-ylmethyl)quinazolin-4(3H)-one (3)
.was purified by PLC (MeOH/EtOAc 6:94, plate run three times
3-((1S,2S)-2-Hydroxycyclohexyl)-8-methyl-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)quinazolin-4(3H)-one (4).
6-( 
3-((1S,2S)-2-Hydroxycyclohexyl
)-7-methyl-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3- yl)methyl)quinazolin-4(3H)-one (5). 6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2- hydroxycyclohexyl)-7-methylquinazolin-4(3H)-
3-((1S,2S)-2-Hydroxycyclohexyl)-7,8-dimethyl-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)quinazolin-4(3H)-one (6) and 3-((1S,2S)-2-Hydroxycyclohexyl)-7,8-dimethyl-6-(pyridin-
3-ylmethyl)quinazolin-4(3H)-one (7).
6-( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Additional H 2 SO 4 (1 mL) was added, and heating continued. After a total of 6 days, the mixture was cooled to RT, and concentrated under reduced pressure. The residue was neutralised with sat.
3-((1S,2S)-2-Hydroxycyclohexyl)-6-((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)pyrido[2,3-d]pyrimidin-4(3H)-one (8).
6-((6-Chloropyridin-3-yl)methyl)-3-((1S
,
6-([1,1'-Biphenyl]-4-ylmethyl)-3-((1S,2S)-2-hydroxycyclohexyl)thieno[2,3-d]pyrimidin-4(3H)-one (9).
5-([1,1'-Biphenyl]-4-ylmethyl)-2-amino-N-((1S,2S)-2-hydroxycyclohexyl
NaHCO 3(aq) , and the resulting precipitate collected by filtration (vacuum), and washed with water.
After drying, 4.452 g (83%) of an off-white solid was obtained. 1 
2-Amino-5-bromo-3-methylbenzoic acid hydrobromide (22).
29 2-Amino-3-methylbenzoic acid (13) (2.08 g, 13.8 mmol) was dissolved in acetic acid (8 mL) and stirred at RT. A solution of bromine 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 28 (2.20 g, 13.8 mmol, 1.0 eq) in acetic acid (2 mL) was added in a dropwise fashion, followed by washings of DCM (5 mL Concentration of dried organic layer under reduced pressure, gave 4.00 g (94%) of a pale brown 
2-Amino-5-bromo-3,4-dimethylbenzoic acid (24).
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)benzamide (25
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)-3-methylbenzamide (26
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)-4-methylbenzamide (27
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)-3,4-dimethylbenzamide (28).
2-Amino-5-bromo-3,4-dimethylbenzoic acid (24) 
6-Bromo-3-((1S,2S)-2-hydroxycyclohexyl)quinazolin-4(3H)-one (29).
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)benzamide (25) (1.18 g, 3.8 mmol) was dispersed in DMF-DMA (12 mL) and heated, with stirring at 85 °C for 3 h. LCMS analysis indicated that the dimethylamine addition product was the major component of the reaction mixture, with elimination to the desired product progressing slowly. Further DMF-DMA (5 mL) was added, and the reaction temperature was increased to 115 °C, with heating continued for 72 h (progress monitored by LCMS). The mixture was cooled to RT and carefully quenched with water (very exothermic), and the resulting precipitate collected by filtration (vacuum) before washing with water. After drying under air, the crude precipitate was recrystallized from EtOH to 767 mg (63%) of a yellow solid. 1 (27) (481 mg, 1.46 mmol) was dispersed in formamide (4 mL) in a 10 mL microwave vial, before sealing and heating at 120 °C with stirring.
6-Bromo-3-((1S,2S)-2-hydroxycyclohexyl)-8-methylquinazolin-4(3H)-one (30). 2-Amino-5-bromo-
N-((1S,2S)-2-hydroxycyclohexyl)-3-methylbenzamide
6-Bromo-3-((1S,2S)-2-hydroxycyclohexyl)-7-methylquinazolin-4(3H)-one (31). 2-Amino-5-bromo-
N-((1S,2S)-2-hydroxycyclohexyl)-4-methylbenzamide
LCMS analysis after this time indicated no reaction progression, so the temperature was increased to 150 °C, and stirring continued for 4 h. LCMS analysis indicated the reaction was complete, so the mixture was cooled to RT overnight, before diluting with water (30 mL), then extracting with 3.63 min. give 33 mg (14%) of an off-white glassy solid. An additional 107 mg (37%) of yellow glassy solid was also isolated form the column, eluting before the desired product, and found to be 6-bromo-7- 1.13 mmol, 0.07 eq) were dispersed in degassed DME (64 mL) and degassed 2 M Na 2 CO 3(aq) (32 mL). The mixture was heated at 70 °C for 22.5 h, then at 100 °C for 3 h, followed by 85 °C overnight. LCMS analysis over this time indicated the Wittig reaction progressed at a faster rate than the Suzuki coupling. The mixture was cooled, then dilute with water (200 mL), before 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 41 describes the underlying stimulus-response coupling of the ligand-occupied receptor to the signal pathway. This parameter was constrained to be shared between all curves within a fitted dataset for each interaction study, and in all instances was not significantly different from unity. In many instances, the individual model parameters of equation 2 could not be directly estimated via the nonlinear regression algorithm by analysis of the functional data alone due to parameter redundancy. To facilitate model convergence, therefore, we fixed the equilibrium dissociation constant of each ligand to that determined from the whole cell binding assays. For compounds where no agonism was observed, logτ B was fixed to -3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
6-Bromo-3-((1S,2S)-2-hydroxycyclohexyl)-7,8-dimethylquinazolin-4(3H)-one (32
6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)quinazolin-4(3H)-one (33)
.
6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)-8-methylquinazolin-4(3H)-one (34). 6-Bromo-3-((1S
,d 6 ) δ 160.5, 149.9, 148.2, 144.9, 144.5, 140.1, 138.4, 136.2, 135.6, 135.2, 124.2
6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)-7-methylquinazolin-4(3H)-one (35)
6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)-7,8-dimethylquinazolin-4(3H)-one (36). 6-Bromo-3-((1S
2-Amino-5-bromo-N-((1S,2S)-2-hydroxycyclohexyl)nicotinamide (38
6-Bromo-3-((1S,2S)-2-hydroxycyclohexyl)pyrido[2,3-d]pyrimidin-4(3H)-one (39)
6-((6-Chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)pyrido[2,3-d]pyrimidin-4(3H)-one (40)
.((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)-7,8-dihydropyrido[2,3- d]pyrimidin-4(3H)-one.
2-Cyano-N-((1S,2S)-2-hydroxycyclohexyl)acetamide (48
